ResMed Inc. (RMD) Financials
Key financial figures for ResMed Inc. (Q1 2027).
Resmed fiscal Q1 2027 revenue rose 6% to $1,415 million (7% core constant currency) with non-GAAP diluted EPS up 14% to $2.91, and FY2027 guidance was left unchanged. Revenue was $1,414.8 million, up 6% year over year (7% on a core constant currency basis, which excludes the Noctrix acquisition and the MatrixCare divestiture), driven by sleep devices and masks and accessories. GAAP diluted EPS was $2.92 (up 23%) and included a $0.38 per share gain on the MatrixCare divestiture; non-GAAP diluted EPS was $2.91 (up 14%) on higher revenue and a 50 basis point gain in non-GAAP gross margin to 62.5%. On the outlook: FY2027 guidance reiterated on October 29, 2026, unchanged from August 6, 2026: core constant currency revenue growth of 5% to 7%, reported revenue of $5.75 billion to $5.85 billion, and non-GAAP diluted EPS of $12.00 to $12.25. Figures are for Q1 FY2027, as ResMed Inc. reported them.
- Revenue
- $1.4B
- Net Income
- $418M
- EPS
- $2.93
- Total Assets
- $8.2B
- Operating Cash Flow
- $422M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q1 FY2027 | $1.4B | $418M | $2.92 | 32.02% | $374M |
| Q4 FY2026 | $1.5B | $383M | $2.64 | 30.66% | $1.6B |
| Q3 FY2026 | $1.4B | $399M | $2.74 | 34.92% | $520M |
| Q2 FY2026 | $1.4B | $393M | $2.68 | 34.97% | $305M |
| Q1 FY2026 | $1.3B | $349M | $2.37 | 33.43% | $414M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2026 | $5.7B | $1.5B | $10.43 | 33.76% | $1.6B |
| FY2025 | $5.1B | $1.4B | $9.51 | 32.75% | $1.7B |
| FY2024 | $4.7B | $1.0B | $6.92 | 28.17% | $1.3B |
Frequently asked questions
What was ResMed Inc.'s revenue last quarter?
ResMed Inc. reported revenue of $1.41 billion for Q1 FY2027, up 5.9% from the same period a year earlier.
Is ResMed Inc. profitable?
Yes. ResMed Inc. reported net income of $418.4 million for Q1 FY2027, a net margin of 29.57% on revenue.
How has ResMed Inc.'s margin trended?
Operating margin was 32.02% in Q1 FY2027, compared with 33.43% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did ResMed Inc. generate?
ResMed Inc. generated free cash flow of $373.7 million in Q1 FY2027, after capital expenditure.
Full income statement, balance sheet and cash flow for ResMed Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.